FDA Inspection
Haematologic Technologies, LLC dba ProlytixHaematologic Technologies, LLC dba Prolytix – FDA Inspection, Jun 27, 2019
Record Details
This FDA Inspection record concerns Haematologic Technologies, LLC dba Prolytix, with an inspection on June 27, 2019, issued by the Center for Biologics Evaluation and Research, covering biologics.
View Company Profile
ID · 50ca8d3d-8097-4872-aed7-441384aec950
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1098078
- FDA center
- Biologics
- Project area
- Blood and Blood Products
- Outcome
- Form 483 issued
Other FDA inspections of Haematologic Technologies, LLC dba Prolytix
6| Date | Classification | Office | Project area |
|---|---|---|---|
| April 17, 2026 | Not classified | New England District Office | |
| January 6, 2025 | Not classified | New England District Office | |
| July 30, 2021 | VAI | Center for Biologics Evaluation and Research | Blood and Blood Products |
| July 28, 2017 | NAI | Center for Biologics Evaluation and Research | Blood and Blood Products |
| May 11, 2017 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Haematologic Technologies, LLC dba Prolytix
- FDA Inspection 1314930 - 2026-04-17
- FDA Inspection 1258523 - 2025-01-06
- FDA Inspection 1147450 - 2021-07-30
- FDA Inspection 1027695 - 2017-07-28
- FDA Inspection 1013147 - 2017-05-11
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.